Eris Lifesciences to buy remaining 30% in Swiss Parenterals for ₹4.23 billion

Eris Lifesciences Ltd. on Monday approved the acquisition of the remaining 30% stake in its subsidiary Swiss Parenterals Ltd. from Naishadh Shah for ₹4.23 billion, to be paid through a preferential issue of equity shares.

Eris will acquire 1.67 million shares, taking its holding to 100% and making Swiss Parenterals a wholly owned subsidiary, the company said in an exchange filing.

To complete the deal, Eris will issue 2.36 million fully paid equity shares to Shah at ₹1,835.35 per share. Shah, a director at Swiss Parenterals, currently oversees a business that reported a turnover of ₹3.5 billion in 2024-25 (Apr–Mar) and supplies parenteral products to 80 countries